Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$0.44
▲ $0.06 (+14.5%)
Market data updated: 09/20 03:19 AM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$2.42M
Day Range
$0.38 - $0.45
52-Week Range
⚠️ Data anomaly
Beta
—
Next Earnings
—
Support
$0.32
Resistance
$2.78
SLXN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-98.8% (1Y)
Strengths: 9/24 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Net income growth
Net income growth: 27.9%
Growth
Biggest negative driver
Daily volatility (ATR)
ATR: 20.3% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
52
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $0.44
Evidence: FOMO score jumped from 22 to 60 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
Not enough data yet to generate this synthesis.
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
46
Quality
No data available
Value
60
Momentum
38
Risk
40
Sentiment
100
Fundamental
46
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Everyone's writing about Silexion Therapeutics Corp. News trend score: 100. Reason: 13 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
53
🎯 Conviction (vs. Emotion)
50
Psychology
60
Fundamentals
46
Technical
38
Valuation
60
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
-84%
Market Narrative
85
Fundamental Reality
50
Narrative Gap
+35
🧠 Market Brain events driving this
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham (Enterprising Investor) — 100/100
🔴 Weakest match
Morgan Housel — 0/100
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 100
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 98
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 90
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 84
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 80
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 64
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 64
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 49
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 36
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 32
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 13
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 0
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (4 bullish · 6 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-457.6%
ROA
-165.1%
ROIC
—
EPS
$8.96
Cash
$5.99M
Total Debt
—
Current Ratio
2.41
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Current Price
$0.44
Estimated Fair Value (DCF)
-$151.94
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-11.91M | $-10.93M |
| 2 | 8.1% | $-12.88M | $-10.84M |
| 3 | 6.3% | $-13.68M | $-10.57M |
| 4 | 4.4% | $-14.28M | $-10.12M |
| 5 | 2.5% | $-14.64M | $-9.51M |
Base FCF (last actual year)
$-10.83M
Terminal Value
$-230.85M
Present Value of Terminal Value
$-150.04M
Enterprise Value
$-202.00M
Net Debt
$0
Equity Value
$-202.00M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$1.96
Tangible Book Value per Share (Tangible NAV)
$1.96
Sentiment based on basic keywords (not AI) — 13 positive, 6 neutral, 1 negative out of the last 20 articles.
ChartMill · 17.9.2026
ChartMill · 15.9.2026
ChartMill · 15.9.2026
Benzinga · 15.9.2026
Benzinga · 15.9.2026
ChartMill · 11.9.2026
Benzinga · 11.9.2026
ChartMill · 11.9.2026
Benzinga · 11.9.2026
ChartMill · 10.9.2026
ChartMill · 10.9.2026
ChartMill · 10.9.2026
Benzinga · 10.9.2026
ChartMill · 10.9.2026
Benzinga · 10.9.2026
Benzinga · 10.9.2026
Yahoo · 9.9.2026
GlobeNewswire · 14.8.2026
Benzinga · 14.8.2026
ChartMill · 12.8.2026
Silexion Therapeutics Corp (SLXN) currently has a StockIQ AI score of 52/100, rated "Moderate" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
SLXN currently scores 52/100 (Moderate) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
SLXN's technical score is 38/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Net income growth: 27.9%; Current ratio: 2.41; MACD histogram is positive — rising momentum.
Based on the real signals StockIQ computed: ATR: 20.3% of price; Calmar: -0.94 (3y annualized return -93.6% / max drawdown 100.0%); Return on equity (ROE): -457.6% (negative).
StockIQ has no recorded dividend payment history for SLXN.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Horenshtein Hadar Mirit | Grant/Award from Employer | 4.6.2026 | 7,500 | +7,500 | — |
| Shirvan Mitchell | Grant/Award from Employer | 4.6.2026 | 6,000 | +6,000 | — |
| Hadar Ilan | Grant/Award from Employer | 4.6.2026 | 10,000 | +10,000 | — |
| Hadar Ilan | Grant/Award from Employer | 4.6.2026 | 16,547 | +10,000 | — |
| Shirvan Mitchell | Grant/Award from Employer | 4.6.2026 | 8,789 | +6,000 | — |
| Horenshtein Hadar Mirit | Grant/Award from Employer | 4.6.2026 | 12,515 | +7,500 | — |
| Shirvan Mitchell | Open Market Sale | 26.3.2026 | 22,818 | -22,818 | $1.36 |
| Shirvan Mitchell | Open Market Sale | 26.3.2026 | 27,889 | -22,818 | $1.36 |
| Peled Amnon | Grant/Award from Employer | 20.2.2026 | 8,904 | +8,904 | — |
| Abramov Dror Yosef | Grant/Award from Employer | 20.2.2026 | 10,685 | +10,685 | — |
| Noy Shlomo | Grant/Award from Employer | 20.2.2026 | 9,091 | +9,091 | — |
| Abramov Dror Yosef | Grant/Award from Employer | 20.2.2026 | 9,091 | +9,091 | — |
| Lushi Avner | Grant/Award from Employer | 20.2.2026 | 9,091 | +9,091 | — |
| Peled Amnon | Grant/Award from Employer | 20.2.2026 | 7,576 | +7,576 | — |
| Alon Ruth | Grant/Award from Employer | 20.2.2026 | 9,091 | +9,091 | — |
| Shirvan Mitchell | Grant/Award from Employer | 20.2.2026 | 49,726 | +49,726 | — |
| Lushi Avner | Grant/Award from Employer | 20.2.2026 | 10,685 | +10,685 | — |
| Hadar Ilan | Grant/Award from Employer | 20.2.2026 | 64,350 | +64,350 | — |
| Alon Ruth | Grant/Award from Employer | 20.2.2026 | 10,685 | +10,685 | — |
| Horenshtein Hadar Mirit | Grant/Award from Employer | 20.2.2026 | 49,726 | +49,726 | — |
| Noy Shlomo | Grant/Award from Employer | 20.2.2026 | 10,685 | +10,685 | — |
| Hadar Ilan | Grant/Award from Employer | 20.2.2026 | 65,471 | +64,350 | — |
| Shirvan Mitchell | Grant/Award from Employer | 20.2.2026 | 50,707 | +49,726 | — |
| Alon Ruth | Grant/Award from Employer | 20.2.2026 | 10,228 | +9,091 | — |
| Alon Ruth | Grant/Award from Employer | 20.2.2026 | 10,685 | +10,685 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
14,501 shares short as of 2026-08-31 · vs. 21,284 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
44.4% of trading volume this week was short selling, vs. 37.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology